Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 9, Issue 9, Pages 3249-3256Publisher
ELSEVIER
DOI: 10.1016/j.jaip.2021.07.029
Keywords
Esophagus; Eosinophil; Food antigen; Diet; Proton pump inhibitor; Corticosteroid; Biologic; Fibrosis; Remodeling
Categories
Funding
- National Institutes of Health [U54-AI117804, R01-AI140133, R01-ES031940, R01-AI092135, R21-AI154353, K24-AI135034, R01-DK114457]
- American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma, and Immunology
Ask authors/readers for more resources
Eosinophilic esophagitis (EoE) is a chronic disease triggered by antigens, with increasing prevalence in children and adults, leading to complications if left untreated. There have been new clinical trials for EoE therapies, including elimination diets, proton pump inhibitors, swallowed topical corticosteroids, and biologics, with a need for future trials to tailor therapies to individual patients.
Eosinophilic esophagitis (EoE) is an antigen-triggered chronic disease of increasing prevalence in children and adults. Untreated or therapy-resistant EoE leads to complications of esophageal food impactions and luminal narrowing. The past decade has seen a number of new clinical trials for EoE therapies including elimination diets, proton pump inhibitors, swallowed topical corticosteroids, and biologics. In this review, we comment on the current state of the art for dietary and pharmacologic management of EoE and the need for future clinical trials to help tailor therapies to individual patients with this chronic disease. (C) 2021 American Academy of Allergy, Asthma & Immunology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available